BRAF and colorectal carcinoma: Despite the advent of targeted treatments, such as BRAF inhibitors and immune checkpoint inhibitors, conventional CT, alone or in combination with bevacizumab, remains a treatment option for patients with RAS- and BRAF-mutant CRC.